Edition:
United Kingdom

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

94.66EUR
22 Oct 2018
Change (% chg)

-- (--)
Prev Close
€94.66
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
461,287
52-wk High
€105.35
52-wk Low
€70.64

Chart for

About

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services... (more)

Overall

Beta: 1.05
Market Cap(Mil.): €4,412.26
Shares Outstanding(Mil.): 50.87
Dividend: --
Yield (%): --

Financials

  GLPG.AS Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -0.58 -- --
ROI: -2.51 0.21 14.27
ROE: -3.05 1.17 15.99

BRIEF-Galapagos Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis

* REPORTED TOGETHER WITH GILEAD SCIENCES ON SUNDAY PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS

22 Oct 2018

BRIEF-Galapagos: Capital Increase Of EUR 2.0 Million

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES

04 Oct 2018

Galapagos, Gilead bask in $4-6 billion new drug sales hope

LONDON Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

12 Sep 2018

UPDATE 1-Galapagos, Gilead bask in $4-6 bln new drug sales hope

LONDON, Sept 12 Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

12 Sep 2018

Galapagos shares soar on $4-6 billion hopes for new drug

LONDON Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

12 Sep 2018

Galapagos shares soar on $4-6 bln hopes for new drug

LONDON, Sept 12 Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.

12 Sep 2018

BRIEF-Galapagos NV reports H1 Group Revenues Of €101.9 Million

* CASH AND CASH EQUIVALENTS ON 30 JUNE 2018 OF €1,066.8 MILLION

02 Aug 2018

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

ZURICH Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

19 Jul 2018

Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug

ZURICH, July 19 Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

19 Jul 2018

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES

21 Jun 2018

Earnings vs. Estimates